The triphosphates of the antiherpesvirus acyclic guanosine analogs 9-[4-hydroxy-2-(hydroxymethyl)butyl] guanine (2HM-HBG), 9-(2-hydroxyethoxymethyl)guanine (acyclovir [ACV]), and 9-(3,4-dihydroxybutyl)guanine (buciclovir) were examined for their effects on partially purified varicella-zoster virus (VZV) DNA polymerase as well as cellular DNA polymerase a. The triphosphate of 2HM-HBG competitively inhibited the incorporation of dGMP into DNA catalyzed by the VZV DNA polymerase. 2HM-HBG-triphosphate (2HM-HBG-TP) had a higher affinity for the dGTP-binding site on the VZV DNA polymerase than did dGTP; apparent Km and Ki values of dGTP and 2HM-HBG-TP were 0.64 and 0.034 p,M, respectively. ACVtriphosphate (ACV-TP) was found to be the most potent inhibitor of VZV DNA polymerase. ACV-TP had a 14 and 464 times better direct inhibitory effect than 2HM-HBG-TP and buciclovir-triphosphate, respectively. The cellular (human embryonic lung fibroblast) DNA polymerase a inhibition was related to viral polymerase inhibition as efficacy ratios: 2HM-HBG-TP had a ratio of more than 1,000, which appeared to be similar to that of ACV-TP.
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Varicella-zoster virus (VZV), a member of the human herpesvirus group, is the causative agent of chicken pox (varicella), one of the most common infectious diseases in children. After the primary infection, VZV frequently persists in a latent stage in the sensory ganglia. Upon reactivation, VZV gives rise to shingles (herpes zoster virus). VZV infections in healthy individuals are usually not serious. However, when the infection occurs in an immunocompromised host, it may cause severe disease and can even be fatal. Occasions for treatment are apparent for several clinical conditions: children with leukemia who encounter VZV; bone marrow and, sometimes, renal transplant patients during the long recovery phase; patients with acquired immunodeficiency syndrome, who may experience severe VZV infections; and more infrequently, patients with VZV encephalitis.
There is a need for a chemotherapeutic remedy, and various antiviral drugs have been studied (6, 11, 12, 20, 23, 31) in clinical trials. Several compounds have also been compared in VZV-infected cell cultures (25) . 9-[4-Hydroxy-2-(hydroxymethyl)butylJguanine (2HM-HBG) was recently reported to be a selective inhibitor of VZV multiplication (1) . Like acyclovir (ACV) (2, 10) , 2HM-HBG is thought to be phosphorylated to the monophosphate form by the VZVinduced thymidine kinase (TK), since TK-variants of VZV are almost resistant to inhibition (G. Abele, A. Karlstrom, J. Harmenberg, B. Lindborg, and B. Wahren, submitted for publication). In comparisons with ACV, 2HM-HBG has been reported to have a higher affinity to VZV TK (1) . This may explain the 10-fold higher antiviral effect of 2HM-HBG to VZV compared with that of ACV in cell cultures. In this study we used the triphosphate of 2HM-HBG (2HM-HBG-TP) to study its antiviral effect and mechanism of inhibition * Corresponding author. on purified VZV DNA polymerase (18) 
RESULTS
Characterization of VZV DNA polymerase. The elution profiles of host cell DNA polymerase a and VZV DNA polymerase on the phosphocellulose chromatography column are shown in Fig. 1 . To investigate whether the polymerase activity was of cellular or viral origin, the enzyme activity was determined with or without the addition of S ,uM PFA. Since less than 1 p.M PFA inhibits VZV DNA polymerase to 50%, whereas about 40 p.M PFA is required to inhibit cellular DNA polymerase a to the same extent (8) , this drug affords a ready means of distinguishing viral enzyme from cellular DNA polymerase a. One peak of cellular DNA polymerase a (not inhibited by PFA) was eluted at 285 mM KCI. VZV DNA polymerase (inhibited by PFA and active without PFA) was found in two smaller peaks at 330 and 350 mM KCI. Fractions 95 to 110 were pooled to represent VZV DNA polymerase.
The HL cellular polymerase a used for kinetic studies was always from noninfected cells and was purified by the same procedure as the VZV-infected cells. Cellular DNA polymerase a from the phosphocellulose chromatography column was eluted at the same location as when it was eluted from the VZV-infected cells. lyzed. All compounds were found to be inhibitors of viral -18 as a template. The straight line shows the gradually DNA polymerization. ACV-TP was found to be the most alt concentrations for fractions 62 to 116, as determined potent inhibitor of this enzyme, followed by 2HM-HBG-TP ivity measurements. (Fig. 3) . Inhibiting concentrations that caused a 50% reduc- Fig. 4 , we conclude that CT DNA polymerase a is more susceptible to inhibition by the studied inhibitors than the HL cell DNA polymerase a. Again, ACV-TP was the most potent inhibitor of the two cellular enzymes. Concentrations of 3.2 and 6.3 ,M ACV-TP caused a 50% reduction of the CT DNA polymerase a and HL DNA polymerase a enzyme activities. With 2HM-HBG, concentrations over 100 FM were required to obtain this reduction for HL cell DNA polymerase a. With BCV-TP we were not able to determine a 50% reduction value; at a concentration of 100 ,uM, 92 to 99% of the enzyme activity was retained. The ratios of anticellular (HL cell) to antiviral polymerase inhibition were in the following order: 2HM-HBG-TP (>1,000) > ACV-TP (900) > BCV-TP (30) .
Enzyme kinetics. The triphosphate of 2HM-HBG was found to be a competitive inhibitor of VZV DNA polymerase activity in the presence of various concentrations of dGTP (Fig. 5) . The apparent Ki value for 2HM-HBG-TP was 0.034 + 0.013 FM (mean + standard deviation). For dGTP the Km value was 0.64 ,uM. The affinity of 2HM-HBG-TP for the VZV DNA polymerase was 19 times higher than that of the competing natural substrate.
DISCUSSION
The nucleoside analog 2HM-HBG is a new and potent inhibitor of VZV (1) and HSV-1 (14) in vitro. The antiviral effect of modified nucleosides is dependent on the presence of phosphorylating enzymes which generate the corresponding nucleoside triphosphates. Several of these triphosphates act selectively on the DNA polymerase level. Many HSV-1 and VZV strains that are resistant to various nucleoside analogs have been described (4, 5, 7, 9, 21, 24, (26) (27) (28) . We and others have previously shown that VZV strains with deficient TK activities have a decreased susceptibility to acyclic guanosine analogs like ACV and 2HM- Cytomegalovirus, which lacks a virus-induced TK, is not susceptible to these compounds but is susceptible to other modified nucleosides that can be phosphorylated by cellular enzymes (15) .
In order to analyze 2HM-HBG efficacy after its activation by VZV TK, VZV DNA polymerase was purified to study the inhibition by 2HM-HBG at the level of this enzyme. To minimize the contamination of VZV DNA polymerase with cellular polymerase a, we improved previous separation methods (17) on phosphocellulose by using different shallow gradients of KCI and elution times. Optimal separation was obtained when a 50 to 500 mM linear gradient of KCI was used over 6 h. Cellular DNA polymerase a was discriminated from viral polymerase with the addition of 5 ,uM PFA in a manner previously reported for phosphonoacetic acid (17) . The enzyme was not strongly dependent on monovalent cations, since the addition of KCI stimulated the polymerase activity only slightly. Instead, high concentrations of KCI markedly decreased the VZV DNA polymerase activity. At 100 mM KCI a 90% inhibition was noted, which is in contrast to the results obtained with other DNA polymerases of the herpesvirus group. These characteristics are more similar to those of cellular DNA polymerase a. However, in the purification of cellular DNA polymerase a from uninfected HL cells, the peak profile eluting off the phosphocellulose column lacked the VZV DNA polymerase enzyme activity peak. The dependence of divalent cations of VZV DNA polymerase has been reported, and an optimal enzyme polymerization was observed at concentrations of 5 to 10 mM MgCl2 (16) . We found a maximal activity at 1 mM MgCl2, whereas a 50% reduction of enzyme activity was noted at 5 mM MgCl2. The discrepancies may be due to the properties of different VZV strains and host cells, as well as different reaction conditions. In studies of the mechanisms of action of antiviral compounds, it is important that all such parameters be optimal.
Results of the kinetic study indicate that 2HM-HBG-TP is directly active on VZV DNA polymerase and is competitive with dGTP for incorporation into the viral DNA. The affinity of 2HM-HBG-TP for the dGTP-binding site on the VZV DNA polymerase was 19 times higher than that of dGTP. This is similar to findings on HSV and VZV multiplication obtained with ACV. ACV-TP appeared to be superior to both 2HM-HBG-TP and BCV-TP in its ability to inhibit the VZV DNA polymerase activity. The higher affinity of 2HM-HBG for the purified VZV TK, compared with the low affinities of ACV and BCV (1, 13) , may explain the totally higher antiviral activity of 2HM-HBG on VZV multiplication in cell culture (1). These results indicate that a functional viral TK is required for ACV, BCV, and 2HM-HBG to become potent inhibitors of VZV multiplication.
The purification of cellular host cell DNA polymerase at was done from mock-infected subconfluent HL cells, because the polymerase activity found in the stationary-phase confluent cells was found to be low. To correlate the inhibitory activity of the triphosphorylated guanosine analogs, we also investigated the effects on purified CT DNA polymerase a. Evaluation of the effect of the guanosine analogs on purified HL and CT cell polymerase at showed that ACV-TP inhibits the cellular polymerase at activity from both cell lines better than do the triphosphates of 2HM-HBG and BCV.
2HM-HBG had a high affinity for VZV TK, and 2HM-HBG-TP had a moderate affinity for VZV DNA polymerase compared with the metabolites of ACV. 2HM-HBG-TP also had a lower inhibitory activity for the cellular polymerase a tested than did ACV-TP. However, the efficacy ratio for 2HM-HBG in comparison with that for ACV may not reveal the in vivo situation, since the inhibitory effects were studied on purified cellular enzymes. In cell culture 2HM-HBG inhibits VZV replication at least 10 times better (1) than ACV and is therefore a candidate for human anti-VZV therapy.
